StockNews.AISignal intelligence
Company intelligence

LPCN

Lipocine Inc. · NASDAQ · Healthcare

Price$1.66-2.92% · −$0.05
Market cap18.38MEquity value
P / E-0.9Trailing ratio
Volume126.73KLatest session
Market data

LPCN price chart

TradingView
Related signals
1 min delayed

Browse public LPCN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

LPCNOct 7, 2026-13.84% since signal

Health Canada Approves TLANDO; Verity Canada Launch Planned by 2026

Health Canada approved TLANDO for male hypogonadism, strengthening Lipocine's NA license with Verity and targeting a 2026 Canada launch. The oral therapy may capture TRT share from injections and gels in a market of about 700k annual prescriptions, with roughly half insured, potentially boosting near- to medium-term revenue and upside if execution is solid.

View signal analysis
Research

Company intelligence